BidaskClub Downgrades Uniqure (NASDAQ:QURE) to Strong Sell

Uniqure (NASDAQ:QURE) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Friday, BidAskClub reports.

Several other analysts also recently issued reports on the company. Wells Fargo & Co downgraded Uniqure from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $90.00 to $56.00 in a research report on Thursday, June 25th. Chardan Capital dropped their target price on Uniqure from $105.00 to $80.00 and set a “buy” rating for the company in a research note on Thursday, June 25th. Mizuho reiterated a “hold” rating and issued a $61.00 target price on shares of Uniqure in a research note on Tuesday, July 14th. ValuEngine lowered Uniqure from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 14th. Finally, Stifel Nicolaus dropped their target price on Uniqure from $86.00 to $78.00 and set a “buy” rating for the company in a research note on Thursday, June 25th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have given a buy rating to the company’s stock. Uniqure presently has an average rating of “Buy” and a consensus price target of $73.92.

QURE traded up $2.34 during trading on Friday, reaching $41.73. 726,949 shares of the stock were exchanged, compared to its average volume of 507,709. The business’s 50 day moving average price is $49.97 and its two-hundred day moving average price is $55.53. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.89 and a quick ratio of 12.89. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of -13.29 and a beta of 1.24. Uniqure has a 1 year low of $36.20 and a 1 year high of $76.69.

Uniqure (NASDAQ:QURE) last issued its quarterly earnings data on Thursday, July 30th. The biotechnology company reported ($0.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.31). Uniqure had a negative net margin of 2,553.30% and a negative return on equity of 42.00%. The company had revenue of $1.54 million during the quarter, compared to analysts’ expectations of $17.87 million. On average, analysts anticipate that Uniqure will post -0.03 EPS for the current year.

In related news, insider Robert Gut sold 26,875 shares of the stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $70.00, for a total value of $1,881,250.00. Also, CEO Matthew C. Kapusta sold 5,626 shares of the stock in a transaction dated Wednesday, July 22nd. The shares were sold at an average price of $42.31, for a total value of $238,036.06. Following the completion of the transaction, the chief executive officer now directly owns 298,525 shares of the company’s stock, valued at approximately $12,630,592.75. The disclosure for this sale can be found here. In the last quarter, insiders sold 40,002 shares of company stock valued at $2,614,652. Insiders own 2.66% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the stock. Sowell Financial Services LLC boosted its holdings in Uniqure by 451.2% in the first quarter. Sowell Financial Services LLC now owns 1,874 shares of the biotechnology company’s stock valued at $89,000 after purchasing an additional 1,534 shares during the last quarter. Brinker Capital Inc. purchased a new position in Uniqure in the fourth quarter valued at about $206,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings in Uniqure by 25.6% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,243 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 661 shares during the last quarter. Royal Bank of Canada boosted its holdings in Uniqure by 20.0% in the first quarter. Royal Bank of Canada now owns 3,874 shares of the biotechnology company’s stock valued at $184,000 after purchasing an additional 645 shares during the last quarter. Finally, Weiss Multi Strategy Advisers LLC bought a new position in Uniqure during the 1st quarter worth approximately $206,000. 79.23% of the stock is owned by hedge funds and other institutional investors.

About Uniqure

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

See Also: What is a Stop Order?

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.